Compare Moderna, Inc. (MRNA) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Virgin Galactic Holdings, Inc. trades at $2.85 (market cap $445.69M). The key difference: Moderna, Inc. is far larger — about 176.5× Virgin Galactic Holdings, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| MRNA | SPCE | |
|---|---|---|
Market Cap | $78.65B | $445.69M |
Volume | 37,373,437 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $203.46 | $7.52 |
52-Week Low | $22.36 | $2.17 |
Typical Hold Time | 59 Days | 69 Days |
Enterprise Value | $74.80B | $409.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Virgin Galactic (SPCE) trades at $2.84, down 5.65% on the day, reflecting ongoing volatility amid a bearish technical signal. The company continues to report significant losses with a net income margin of -23,867.44% (2025 financials), though it has beaten EPS estimates in recent quarters. Cash flow remains negative, but the trend is improving, with management targeting positive quarterly cash flow by 2027. Recent news highlights strong ticket demand but also a delay in commercial Delta flights to February 2027.
The outlook remains high-risk due to persistent losses and cash burn, but long-term potential exists in commercial spaceflight. Investment opportunity hinges on successful execution of the Delta program and achieving profitability targets. Key risks include execution delays, high cash burn, competitive pressures, and stock dilution. Analyst sentiment is mixed, with 29.41% buy ratings, reflecting cautious optimism amid substantial operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
